Evidence map›Paper›PMID 34262437›Full record

ArticleFrontiers in cellular neuroscience2021

The Cannabinoid Receptor 1 Reverse Agonist AM251 Ameliorates Radiation-Induced Cognitive Decrements.

Vipan K Parihar, Amber Syage, Lidia Flores, Angelica Lilagan, Barrett D Allen, Maria C Angulo, Joseph Song, Sarah M Smith, Rebecca J Arechavala, Erich Giedzinski and 1 more

Open access · goldAbstract read
In one paragraph

Article in Frontiers in cellular neuroscience, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed, 1 pooled it
0.9field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 1 synthesis or guideline pooled it, 11 citations in OpenAlex.

  1. Effects of radiotherapy on the hippocampus and hippocampal neurogenesis: a systematic review of preclinical studies.Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al] · 2025
    Pooled it
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. Review
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 1 institution in 1 country.

Vipan K PariharDepartment of Radiation Oncology, University of California, Irvine, Irvine, CA, United States.
Amber SyageDepartment of Radiation Oncology, University of California, Irvine, Irvine, CA, United States.
Lidia FloresDepartment of Radiation Oncology, University of California, Irvine, Irvine, CA, United States.
Angelica LilaganDepartment of Radiation Oncology, University of California, Irvine, Irvine, CA, United States.
Barrett D AllenDepartment of Radiation Oncology, University of California, Irvine, Irvine, CA, United States.
Maria C AnguloDepartment of Radiation Oncology, University of California, Irvine, Irvine, CA, United States.
Joseph SongDepartment of Radiation Oncology, University of California, Irvine, Irvine, CA, United States.
Sarah M SmithDepartment of Radiation Oncology, University of California, Irvine, Irvine, CA, United States.
Rebecca J ArechavalaDepartment of Radiation Oncology, University of California, Irvine, Irvine, CA, United States.
Erich GiedzinskiDepartment of Radiation Oncology, University of California, Irvine, Irvine, CA, United States.
Charles L LimoliDepartment of Radiation Oncology, University of California, Irvine, Irvine, CA, United States.
University of California, Irvine · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Despite advancements in the radiotherapeutic management of brain malignancies, resultant sequelae include persistent cognitive dysfunction in the majority of survivors. Defining the precise causes of normal tissue toxicity has proven challenging, but the use of preclinical rodent models has suggested that reductions in neurogenesis and microvascular integrity, impaired synaptic plasticity, increased inflammation, and alterations in neuronal structure are contributory if not causal. As such, strategies to reverse these persistent radiotherapy-induced neurological disorders represent an unmet medical need. AM251, a cannabinoid receptor 1 reverse agonist known to facilitate adult neurogenesis and synaptic plasticity, may help to ameliorate radiation-induced CNS impairments. To test this hypothesis, three treatment paradigms were used to evaluate the efficacy of AM251 to ameliorate radiation-induced learning and memory deficits along with disruptions in mood at 4 and 12 weeks postirradiation. Results demonstrated that acute (four weekly injections) and chronic (16 weekly injections) AM251 treatments (1 mg/kg) effectively alleviated cognitive and mood dysfunction in cranially irradiated mice. The beneficial effects of AM251 were exemplified by improved hippocampal- and cortical-dependent memory function on the novel object recognition and object in place tasks, while similar benefits on mood were shown by reductions in depressive- and anxiety-like behaviors on the forced swim test and elevated plus maze. The foregoing neurocognitive benefits were associated with significant increases in newly born (doublecortin+) neurons (1.7-fold), hippocampal neurogenesis (BrdU+/NeuN+mature neurons, 2.5-fold), and reduced expression of the inflammatory mediator HMGB (1.2-fold) in the hippocampus of irradiated mice. Collectively, these findings indicate that AM251 ameliorates the effects of clinically relevant cranial irradiation where overall neurological benefits in memory and mood coincided with increased hippocampal cell proliferation, neurogenesis, and reduced expression of proinflammatory markers.

Indexed as

AM251cranial irradiationHMGB1mood and memory deficitsneurogenesis

Identifiers

PMID34262437
PMCPMC8273551
OpenAlexW3175725576

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.